Scalper1 News
Big-cap biotech Gilead Sciences (GILD) is expected to report a modest Q4 after the close Tuesday, but analysts and investors will be listening closely for new details on the rollout of its potential blockbuster hepatitis C drug Sovaldi. Analysts polled by Thomson Reuters estimate that Gilead’s revenue rose 10% over the year-earlier quarter to $2.85 billion, with profit flat at 50 cents a share. However, the bottom line has been held down by Scalper1 News
Scalper1 News